Is NCT04171323 recruiting in San Francisco, CA?

Yes, NCT04171323 is currently recruiting participants at its San Francisco, CA location. This age-related cognitive decline clinical trial is actively enrolling qualified participants.

Is participation in this San Francisco clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Age-related Cognitive Decline Clinical Trial in San Francisco, CA

Q: How do I join the age-related cognitive decline clinical trial in San Francisco?

To join this clinical trial in San Francisco, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Age-related Cognitive Decline Study in San Francisco

Older adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown. The aim is to discover the most efficacious combination of CT exercises as compared to cognitive stimulation (which will serve as a stringent, active control) to modify the functional trajectories of older adults' with MCI, who are at high risk for dementia. The primary objective of the U01 phase was to design and pilot-test an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). In the R01 phase, the objective is to identify the best combination of CT exercises to delay dementia onset among persons with MCI. The longitudinal endpoint goal is reducing incident dementia. The primary aim of the study is to determine which CT combination has the best probability to delay dementia by producing the largest IADL improvements. The study further aims to explore neuroimaging and novel blood-based biomarkers.

Sponsor: University of Alabama at Birmingham

Who Can Participate

Inclusion Criteria

55 to 89 years of age

Montreal Cognitive Assessment Score of 18-27 inclusive

History of some change in cognitive function relative to established baseline and either 1) a CDR of 0.5; or 2) CDR of 0 and a clinical diagnosis of mild cognitive impairment (MCI) based on a multidisciplinary evaluation that included standardized neuropsychological testing

If reports use of medications typically prescribed for dementia such as Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, or Reminyl, dose has been stable for at least 30 days

Adequate auditory capacity to understand normal speech. No greater than moderate hearing loss evident by thresholds less than or equal to 50 dB at 1000 and 2000 Hz in at least one ear determined by an audioscope.

Adequate visual capacity to read from a computer screen at a normal viewing distance as measured by binocular visual acuity of 20/50 or better tested with a standard near visual acuity chart

Reports and shows adequate motor capacity to touch a computer screen or control a computer mouse.

Wiling to complete all study activities

Willing and capable of providing informed consent

Ability to understand study procedures and comply with them for the length of the study

Exclusion Criteria

Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition

Dementia diagnosis

Clinical Dementia Rating Scale of 1 or greater

History of large vessel stroke with significant residual motor or cognitive impairment

History of moderate to severe traumatic brain injury with residual cognitive symptoms

History of brain tumor

Undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening

Congestive heart failure diagnosis

Primary diagnosis of idiopathic Parkinson's disease

Multiple sclerosis or Amyotrophic lateral sclerosis (ALS) diagnosis

Evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities.

Evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (e.g., unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen)

Geriatric Depression short scale score \>5/15. Participants with mood disorders that are treated and stable and have a GDS score \< 6/15 are not excluded.

Any other clinically significant or unstable medical condition (e.g., ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the assessor's opinion would interfere with the ability to carry out study activities.

Previous participation in 10 or more hours of a computerized cognitive intervention program in the past two years

Previous participation in cognitive intervention research at the study site in the past 2 years

Planning on going away or being otherwise unavailable for a period of more than three weeks in the six months following screening

Contraindications to MRI such as pacemaker, metal implants in body, or claustrophobia

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT04171323) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Age-related Cognitive Decline Treatment Options in San Francisco, CA

If you're searching for age-related cognitive decline treatment options in San Francisco, CA, this clinical trial (NCT04171323) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced age-related cognitive decline specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all age-related cognitive decline clinical trials near you to find additional studies recruiting in your area.

Age-related Cognitive Decline Clinical Trial in San Francisco, CA

Expert Care in San Francisco

IRB Approved

No-Cost Care

Apply for This San Francisco Location

Why Participate?

Simple Process